Epiminder Ltd. · ASX:EPI
Epiminder — Investor Presentation (July 2026)
29 slides from Epiminder's investor presentation, Jul 30, 2026
Slide 1: FY26 Investor Presentation
FY26 Investor Presentation Epiminder Limited (ASX:EPI) 30 July 2026
Slide 2: Disclaimer
DISCLAIMER This disclaimer applies to this presentation and the information contained in it (the “Presentation”). are beyond Epiminder’s control, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. Actual results may be materia
Slide 3: An Experienced Leadership Team
ABOUT EPIMINDER AN EXPERIENCED LEADERSHIP TEAM Dr Rohan Hoare Mark McLellan Dr John Heasman Prof Mark Cook, AO Chief Executive Officer CFO and Company Secretary Chief Operating Officer Chief Medical Officer PhD in Physics (Harvard). 25+ years in 30+ years in finance, including CFO roles at PhD, Univ
Slide 4: Epiminder is developing a new standard in long-term brain monitoring
ABOUT EPIMINDER A differentiated medtech opportunity addressing a major unmet need in drug-resistant epilepsy Epiminder is developing a new standard in long-term brain monitoring for people living with drug-resistant epilepsy. ▪ The Company's FDA-authorised Minder® System is designed for continuous,
Slide 5: Investment Case
INVESTMENT CASE at N ww
Slide 6: Targeting a major unmet need in drug-resistant epilepsy
INVESTMENT HIGHLIGHTS Targeting a major unmet need in drug-resistant epilepsy Large underserved market Reimbursement pathway progressing ~1.1 million1 US adults have drug-resistant epilepsy Coding & Medicare payment established; DETECT and lack reliable long-term seizure monitoring study generating
Slide 7: FY26 and FY27YTD Highlights
INVESTMENT HIGHLIGHTS FY26 AND FY27YTD HIGHLIGHTS 01 02 03 04 DETECT momentum Next-generation Minder Reimbursement progress Strong financial position 50 ~200 devices manufactured 2026 Medicare payment to A$75.8m cash and in testing hospital US$27,700 patients enrolled Strong funding position going 2
Slide 8: Market Need and Opportunity
MARKET NEED AND OPPORTUNITY
Slide 9: Target Market
MARKET OPPORTUNITY Target Market An initial revenue opportunity of up to US$1.1 billion annually1 US Epilepsy Market 3.4m People with epilepsy in the US 1.1M ~25,000-45,000 inconclusive EMU US adults with (epilepsy monitoring unit) patient drug-resistant epilepsy assessments each year × ~US$25k Mind
Slide 10: Current monitoring methods provide an incomplete picture
MARKET OPPORTUNITY Current monitoring methods provide an incomplete picture Patient diaries remain the only current option for long-term monitoring, but they are highly inaccurate : (1) Seizures are often missed Reported events and Seizures may be random, infrequent or electrographic seizures repres
Slide 11: Long-term EEG data to support better treatment decisions
OUR SOLUTION Long-term EEG data to support better treatment decisions Capture missed Generate objective 1 2 FDA cleared events long-term data For adults aged 18–75 Records seizure activity Provides continuous with drug-resistant that short-term EEG data over months epilepsy. monitoring may not and y
Slide 12: An integrated system for long-term EEG monitoring
ABOUT MINDER ® An integrated system for long-term EEG monitoring Implant Wearable App Cloud Sub-scalp electrode and Powers the implant, Transfers EEG data Enables healthcare telemetry unit receives EEG data from securely to the cloud and professionals to access continuously record and the implant an
Slide 13: Minder has demonstrated actionable clinical insight
CLINICAL EVIDENCE Minder has demonstrated actionable clinical insight UMPIRE clinical study(1) Clinician feedback The [Minder] device will transform epilepsy. ~88% – Epileptologist, Stanford of patients received meaningful and actionable clinical insight Absolutely this could be useful for diagnosti
Slide 14: Clinical Validation and Commercialisation
CLINICAL VALIDATION AND COMMERCIALISATION
Slide 15: DETECT Study: Building the evidence base
DETECT STUDY Building the evidence base for reimbursement and commercial adoption Study Design Purpose Prospective, randomised, controlled, blinded, Designed to demonstrate the cost- Type effectiveness and clinical value of Minder in multi-centre US clinical practice to support payer Sites Up to 25
Slide 16: Accelerating enrolment ahead of original forecast
DETECT STUDY Accelerating enrolment ahead of original forecast 20 Sites Forecast Enrolment Profile 210 Achieved Forecast 150 x3 100 75 50 25 + 11 more 1 3 Jan Feb May People live with Mid July epilepsy globally Forecast May Mid-Q3 CY26 Sep 26 H1 CY2027 16
Slide 17: DETECT Study Sites across the US
DETECT STUDY S t u d y S i t e s a c r o s s t h e U S , ~ 7 % o f U S C E C (1) Participating Sites 1. University of Pennsylvania 2. Beth Israel Deaconess Medical Centre 3. Duke University 4. Nicklaus Children's Hospital 5. Mayo Clinic – Arizona 6. Mayo Clinic – Jacksonville 7. Mayo Clinic – Roches
Slide 18: Strong clinical engagement – recent US tour by CMO
DETECT STUDY Strong clinical engagement – recent US tour by CMO KEY TAKEAWAYS 10 institutions, more than 100 neurologists engaged in June and July Beth Israel Deaconess Duke University UC Irvine Strong and growing interest in Minder, particularly for inconclusive diagnoses Clinicians are identifying
Slide 19: Preliminary CY2027 Medicare reimbursement increase supports target US pricing
REIMBURSEMENT UPDATE Preliminary CY2027 Medicare reimbursement increase supports target US pricing 35 Favourable direction in US 31.6 TBD - Nov hospital reimbursement 30 27.7 Supports targeted Minder 25 22.5 System pricing 20 CY2027 Final Rule 15 expected in November 10 Potential additional payment
Slide 20: On track for H1 CY2027 design completion
NEXT-GENERATION DEVICE On track for H1 CY2027 design completion Approximately 200 next generation devices have now KEY IMPROVEMENTS been manufactured for: ▪ Biocompatibility testing Slimmer telemetry unit to ▪ Functional testing support easier implantation Advanced communications and data storage Ex
Slide 21: Growing long term EEG datasets key to future AI and analytics
DATA, AI, FORECASTING Growing Long term EEG datasets key to future AI and analytics Longest continuous EEG dataset Growing volume of longitudinal patient data Algorithmic and AI tools in development Potential future applications in seizure forecasting Potential opportunities to monetise – pharma, fo
Slide 22: Phased commercial rollout through leading US epilepsy centres
COMMERCIALISATION PATHWAY Epiminder intends to undertake a phased commercial rollout through leading US epilepsy centres ahead of a broader commercial launch expected in H1 CY2028 01 02 03 04 05 Next-Gen Early Proof Payer & Commercial DETECT Study Device Points Physician Launch Complete study and Ad
Slide 23: Funded to execute key value-driving milestones
FINANCIAL POSITION Funded to execute key value-driving milestones A$89.5M – ~A$14M Cash Outflow 2H FY26 $14m A$75.8M A$45-48M Funded well into CY2028 Next-Gen R&D ~$15M A$75.8 million cash at 30 June 2026, with no borrowings Employment ~$15M FY27 cash outflow expected to be A$45–48 million, reflecti
Slide 24: Clear milestones over the next 18 months
CORPRATE OUTLOOK Clear milestones over the next 18 months 01 02 03 04 DETECT Study Next-generation Minder Commercial Readiness Financial Outlook ▪ Complete enrolment of ▪ Complete device ▪ Progress early revenue ▪ Expected FY27 cash outflow 210 patients by H1 development in H1 CY2027 opportunities o
Slide 25: Contact
CONTACT COM PANY INVESTOR RELATIONS Gabriella Hold investors@epiminder.com The Capital Network gaby@thecapitalnetwork.com.au (+ 61 2) 7257 7338 25
Slide 26: Appendix
Appendix 26
Slide 27: Profit & Loss (Unaudited)
PROFIT & LOSS (UNAUDITED) $m 1H FY26 2H FY26 FY26 FY25 Interest Income 0.4 1.7 2.1 0.4 • 1H FY26 incurred lower operating expenses in the run up to capital raising Employment Expenses (4.3) (5.5) (9.8) (6.9) in Dec 2025. DETECT Costs (0.5) (5.1) (5.6) (0.8) R&D Costs (G1 + G0) (4.9) (6.8) (11.7) (11
Slide 28: Balance Sheet
BALANCE SHEET $m FY26 FY25 Cash and Cash Equivalents 75.8 8.9 • Balance sheet and capital position Prepayments, GST receivable 1.7 0.5 significantly strengthened because of IPO Current Assets 77.5 9.4 capital raise. Fixed Assets 0.1 0.1 Intangible Assets 13.2 13.2 Non Current Assets 13.2 13.2 • ~$76
Slide 29: Cash Flow Statement
CASH FLOW STATEMENT $m 1H FY26 2H FY26 FY26 FY25 • Operating cash flows in 2H FY26 of ~$14.0m lower than original $20m Interest Received 0.4 1.1 1.5 0.4 guidance due to slow invoicing for DETECT Costs (0.3) (2.0) (2.3) (0.8) DETECT. G1 Costs (4.9) (6.4) (11.2) (10.3) Staff Costs (4.3) (4.4) (8.8) (6